Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04348370 · ClinicalTrials.gov registry record · Phase 4
BCG Vaccine for Health Care Workers as Defense Against COVID 19
A Phase 4 study, sponsored by Texas A&M University.
- Completed
- Registry status
- Phase 4
- Development phase
- 659
- Enrollment target
NCT04348370 is a Phase 4 study that has completed, run by Texas A&M University. The registered enrollment target is 659 participants.
The verdict
NCT04348370, a Phase 4 study, has completed, sponsored by Texas A&M University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 659 participants
- Enrollment target
Study Summary
SARS-CoV-2 spreads rapidly throughout the world. A large epidemic would seriously challenge the available hospital capacity, and this would be augmented by infection of healthcare workers (HCW). Strategies to prevent infection and disease severity of HCW are, therefore, desperately needed to safeguard continuous patient care. Bacille Calmette-Guérin (BCG) is a vaccine against tuberculosis, with protective non-specific effects against other respiratory tract infections in in vitro and in vivo studies, and reported morbidity and mortality reductions as high as 70%. Furthermore, in our preliminary analysis, areas with existing BCG vaccination programs appear to have lower incidence and mortality from COVID191. The investigators hypothesize that BCG vaccination can reduce HCW infection and disease severity during the epidemic phase of SARS-CoV-2.
Interventions
- BIOLOGICAL Placebo Vaccine
- BIOLOGICAL BCG Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 659 participants |
| Start Date | 2020-04-20 |
| Est. Completion | 2023-04-21 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04348370
The ClinicalTrials.gov registry entry for NCT04348370 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 659 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Texas A&M University, which has 95 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Vaccine is the first listed.
NCT04348370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04348370 about?
NCT04348370 is a clinical study titled "BCG Vaccine for Health Care Workers as Defense Against COVID 19". SARS-CoV-2 spreads rapidly throughout the world. A large epidemic would seriously challenge the available hospital capacity, and this would be augmented by infection of healthcare workers (HCW). Strategies to prevent infection and disease severity of HCW are, therefore, desperately needed to safegua...
What is the current status of trial NCT04348370?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 659 participants. The study started on 2020-04-20. Estimated completion is 2023-04-21.
What interventions are being tested in trial NCT04348370?
The interventions under investigation include: Placebo Vaccine (BIOLOGICAL), BCG Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04348370?
This trial is sponsored by Texas A&M University, which has 95 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.